Stock IBIO IBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News iBio, Inc.

Equities

IBIO

US4510337086

Delayed Nyse
Other stock markets
 10:48:22 2024-04-29 EDT 		5-day change 1st Jan Change
1.76 USD 0.00% Intraday chart for iBio, Inc. -0.56% +29.20%
04-01 IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors CI
03-28 Top Premarket Gainers MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors
CI
Top Premarket Gainers
MT
Top Midday Gainers
MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data
MT
Transcript : IBio, Inc. - Special Call
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings
MT
Top Premarket Gainers
MT
IBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
AQ
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
CI
IBio Announces $15.0 Million Private Placement
AQ
IBio, Inc. announced that it has received $14 million in funding
CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka
DJ
IBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
AQ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..
CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
IBio Announces Participation in 23rd Annual PepTalk Conference
AQ
IBio Amends and Extends Maturity of Credit Agreement
AQ
Top Midday Decliners
MT
IBio, Inc. Announces Pricing of $4.5 Million Public Offering
AQ
Top Premarket Decliners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBIO Stock
  4. News iBio, Inc.